ASC Coding, Billing & Collections

After Mylan settled a case where it was accused of purposefully misclassifying its EpiPens to overcharge Medicaid, it is being allowed a six month grace period to continue paying the Centers for Medicare and Medicaid Services its current, wrongly-classified rate,…

Although the 170 million American workers with employer-sponsored health plans will see rising coverage prices in 2017, the increases won't be as striking as witnessed in previous years, according to Reuters.

The American Academy of Family Physicians penned a letter to CMS urging the agency to ensure its rules about the health insurance exchanges work to improve both patient access and outcomes.

During the second presidential debate, Donald Trump proposed repealing the Affordable Care Act and permitting payers to sell policies across state lines. Insurance Business tackled the possibility of the presidential candidate's proposal.

TheStreet is reporting that investors bid up Mylan's stock after the pharmaceutical company settled with the U.S. Department of Justice.

States are adapting to a rapidly rising price tag for prescription drugs through Medicaid, The Hill reports.

A court official supported the Department of Justice's request for Anthem and Cigna to release documents that show the companies fighting over their merger agreement, according to Bloomberg.

After several insurer's pulled out of the ACA, the government will select an option for the affected consumers if they don't enroll in or opt out of the exchanges, the New York Times reports.

The second presidential debate spotlighted healthcare, with Hillary Clinton and Donald Trump arguing about the future of the Affordable Care Act, according to Healthcare IT News.

Mylan agreed to pay the U.S. Department of Justice $465 million to settle questions regarding the classification of the business's EpiPen. Here's what you need to know.